ClinicalTrials.gg

TargetBeta

CLDN18

claudin 18 · also SFTPJ · Claudins

14 programs in company-led studies act on CLDN18, from 10 companies: 8 in phase 3, 1 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (9 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
zolbetuximabruleAstellas Pharmaphase 4127 running–NCIt
garetatug rezetecanJiangsu HengRui Medicinephase 376 running–the company's pipeline
sonesitatug vedotinAstraZenecaphase 376 running–a judged reading
Anti-Claudin18.2/Anti-CD3 Bispecific Antibody QLS31905ruleQilu Pharmaceuticalphase 365 runningCD3ENCIt
arcotatug tavatecanruleInnovent Biologicsphase 355 running–NCIt
tecotabart vedotinSino Biopharmaceuticalphase 363 running–the company's pipeline
Anti-Claudin 18.2 Antibody-drug Conjugate BL-M05D1Biokin (Shanghai) Biopharmaceuticalphase 333 running–the company's pipeline
emaretamigruleAstellas Pharmaphase 333 runningCD3ENCIt
terallethrinruleFutureGen Biopharmaceutical (Beijing)phase 333 running–NCIt
Anti-Claudin 18.2 Antibody-drug Conjugate MK-1200ruleSichuan Kelun Pharmaceuticalphase 232 running–NCIt
Anti-Claudin 18.2 Antibody-drug Conjugate ASP546CruleAstellas Pharmaphase 222 running–NCIt
givastomigruleI-Mab Biopharma USphase 222 running–NCIt
Anti-Claudin 18.2 Antibody-drug Conjugate AZD4360ruleAstraZenecaphase 211 running–NCIt
Anti-Claudin18.2/Anti-CD3 Bispecific Antibody AZD5863AstraZenecaphase 211 runningCD3Ea judged reading

Also acted on by the same programs

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.